Literature DB >> 25112467

The effect of proinflammatory cytokines on IL-17RA expression in NSCLC.

Qi Huang1, Jiao Du, Jinshuo Fan, Zhilei Lv, Xin Qian, Xiuxiu Zhang, Jieli Han, Caiyun Chen, Feng Wu, Yang Jin.   

Abstract

Interleukin-17 receptor (IL-17RA) is essential for proinflammatory cytokine IL-17-mediated pathogenesis of various tumors. IL-17RA is upregulated by some proinflammatory cytokines such as IL-21 and IL-15 and downregulated by IL-2, while the effect of IL-1β, IL-6, IL-8, TNF-α on IL-17RA expression in non-small cell lung caner (NSCLC) remains unknown. Our findings revealed that IL-17RA mRNA was increased in NSCLC tissues compared with the corresponding peritumor tissues (P = 0.0039) and high expression of IL-17RA protein in human NSCLC tissues was significantly associated with histological subtype, primary tumor size and clinical stages (P = 0.033, 0.033 and 0.011, respectively). IL-17RA mRNA expression was positively related to IL-1β, IL-6, IL-8, TNF-α mRNA expression (P = 0.013, 0.0001, 0.002 and 0.010 respectively) in NSCLC tissues. Furthermore, IL-1β, IL-6, IL-8, TNF-α upregulated IL-17RA mRNA and protein in A549 and H460 cells (all P < 0.05). It is suggested that IL-1β, IL-6, IL-8, TNF-α promoted IL-17RA expression in NSCLC and they may involve in IL-17RA signaling in NSCLC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25112467     DOI: 10.1007/s12032-014-0144-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  41 in total

1.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.

Authors:  J Brognard; A S Clark; Y Ni; P A Dennis
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

Review 2.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 3.  Interleukin-17 and its receptor.

Authors:  M K Spriggs
Journal:  J Clin Immunol       Date:  1997-09       Impact factor: 8.317

4.  Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression.

Authors:  Sophie Kirshberg; Uzi Izhar; Gail Amir; Jonathan Demma; Fiona Vernea; Katia Beider; Zippora Shlomai; Hanna Wald; Gideon Zamir; Oz M Shapira; Amnon Peled; Ori Wald
Journal:  PLoS One       Date:  2011-09-15       Impact factor: 3.240

5.  IL-6 induces neuroendocrine dedifferentiation and cell proliferation in non-small cell lung cancer cells.

Authors:  Kuo-Ting Chang; Chun-Ming Tsai; Yih-Chy Chiou; Chao-Hua Chiu; King-Song Jeng; Chi-Ying F Huang
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-05-13       Impact factor: 5.464

6.  Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: Enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells.

Authors:  Xi Chen; Qichao Xie; Xiaoming Cheng; Xinwei Diao; Yue Cheng; Jiankun Liu; Wei Xie; Zhengtang Chen; Bo Zhu
Journal:  Cancer Sci       Date:  2010-09-01       Impact factor: 6.716

7.  Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis.

Authors:  A Kehlen; K Thiele; D Riemann; J Langner
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

8.  Differential regulation of the IL-17 receptor by gammac cytokines: inhibitory signaling by the phosphatidylinositol 3-kinase pathway.

Authors:  Matthew J Lindemann; Zihua Hu; Marta Benczik; Kathleen D Liu; Sarah L Gaffen
Journal:  J Biol Chem       Date:  2008-03-17       Impact factor: 5.157

9.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.

Authors:  Marc Veldhoen; Richard J Hocking; Christopher J Atkins; Richard M Locksley; Brigitta Stockinger
Journal:  Immunity       Date:  2006-02       Impact factor: 31.745

10.  Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.

Authors:  Rong Zeng; Rosanne Spolski; Steven E Finkelstein; SangKon Oh; Panu E Kovanen; Christian S Hinrichs; Cynthia A Pise-Masison; Michael F Radonovich; John N Brady; Nicholas P Restifo; Jay A Berzofsky; Warren J Leonard
Journal:  J Exp Med       Date:  2005-01-03       Impact factor: 14.307

View more
  5 in total

1.  IL-17 induces EMT via Stat3 in lung adenocarcinoma.

Authors:  Qi Huang; Jieli Han; Jinshuo Fan; Limin Duan; Mengfei Guo; Zhilei Lv; Guorong Hu; Lian Chen; Feng Wu; Xiaonan Tao; Juanjuan Xu; Yang Jin
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

2.  IL-17 Promotes Angiogenic Factors IL-6, IL-8, and Vegf Production via Stat1 in Lung Adenocarcinoma.

Authors:  Qi Huang; Limin Duan; Xin Qian; Jinshuo Fan; Zhilei Lv; Xiuxiu Zhang; Jieli Han; Feng Wu; Mengfei Guo; Guorong Hu; Jiao Du; Caiyun Chen; Yang Jin
Journal:  Sci Rep       Date:  2016-11-07       Impact factor: 4.379

3.  Association of Polymorphisms in Inflammation Genes With the Prognosis of Advanced Non-Small Cell Lung Cancer Patients Receiving Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Authors:  Xuelin Zhang; Tengfei Ye; Mingdong Li; Hongwang Yan; Hui Lin; Hongsheng Lu; Zecheng Qi; Haihui Sheng; Chunya He
Journal:  Front Oncol       Date:  2022-03-18       Impact factor: 6.244

Review 4.  Insights into the Mechanisms of Action of Proanthocyanidins and Anthocyanins in the Treatment of Nicotine-Induced Non-Small Cell Lung Cancer.

Authors:  Naser A Alsharairi
Journal:  Int J Mol Sci       Date:  2022-07-18       Impact factor: 6.208

5.  Potential Impacts of Interleukin-17A Promoter Polymorphisms on the EGFR Mutation Status and Progression of Non-Small Cell Lung Cancer in Taiwan.

Authors:  Kai-Ling Lee; Tsung-Ching Lai; Yao-Chen Wang; Pei-Chun Shih; Yi-Chieh Yang; Thomas Chang-Yao Tsao; Tu-Chen Liu; Yu-Ching Wen; Lun-Ching Chang; Shun-Fa Yang; Ming-Hsien Chien
Journal:  Genes (Basel)       Date:  2021-03-17       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.